Mesenchymal Stem Cell Therapy: Hope for Patients With Systemic Lupus Erythematosus

Li, Aifen; Guo, Feng-Biao; Pan, Quanren; Chen, Shuxian; Chen, Jiaxuan; Liu, Huafeng

doi:10.3389/fimmu.2021.728190

Cited by 47 publications

(43 citation statements)

References 131 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the last two decades, there has been considerable data accumulated on applications of MSC for various autoimmune diseases. This is through the pioneering work mostly by the investigators of Far East and Middle East in single center-based trials at various academic institutions ( 64 , 71 – 73 ). The major rheumatological illnesses studied, so far, include SLE, SSC, and Rheumatoid Arthritis (RA).…”

Section: Msc Treatment Of Autoimmune Diseases—overview Of Publish Datamentioning

confidence: 99%

“…Laboratory parameters showed significant improvement in proteinuria and cytopenia, serum albumin and complement levels. Initial reports included decreased titers of double stranded DNA antibody, as well as increased blood T-regulatory (Treg) cells (CD4 + CD25 + Foxp3 +)—and decreased Th17- populations in the peripheral blood samples ( 73 , 78 ). A follow-up case report on two lupus patients treated with autologous MSC also had increased Treg cells, but the clinical improvement was marginal ( 79 ).…”

Section: Msc Treatment Of Autoimmune Diseases—overview Of Publish Datamentioning

confidence: 99%

See 1 more Smart Citation

Cell Based Treatment of Autoimmune Diseases in Children

Jones

McCurdy

2022

Front. Pediatr.

View full text Add to dashboard Cite

Mesenchymal stem cells have recently been recoined as medicinal signaling cells (MSC) for their ability to promote tissue homeostasis through immune modulation, angiogenesis and tropism. During the last 20 years, there has been a plethora of publications using MSC in adults and to lesser extent neonates on a variety of illnesses. In parts of the world, autologous and allogeneic MSCs have been purified and used to treat a range of autoimmune conditions, including graft versus host disease, Crohn’s disease, multiple sclerosis, refractory systemic lupus erythematosus and systemic sclerosis. Generally, these reports are not part of stringent clinical trials but are of note for good outcomes with minimal side effects. This review is to summarize the current state of the art in MSC therapy, with a brief discussion of cell preparation and safety, insights into mechanisms of action, and a review of published reports of MSC treatment of autoimmune diseases, toward the potential application of MSC in treatment of children with severe autoimmune diseases using multicenter clinical trials and treatment algorithms.

show abstract

Section: Msc Treatment Of Autoimmune Diseases—overview Of Publish Datamentioning

confidence: 99%

Section: Msc Treatment Of Autoimmune Diseases—overview Of Publish Datamentioning

confidence: 99%

Cell Based Treatment of Autoimmune Diseases in Children

Jones

McCurdy

2022

Front. Pediatr.

View full text Add to dashboard Cite

show abstract

“…Systemic lupus erythematosus (SLE) is a typical autoimmune disease characterized by excessive activation of T and B cells, producing a large number of autoantibodies and pro-inflammatory cytokines that result in tissue and organ damage ( 1 ). At present, there are few clinically approved traditional therapeutic drugs and biologic therapies for SLE ( 2 , 3 ). Animal models have made great contributions to the study of SLE pathogenesis and the development of new drugs.…”

Section: Introductionmentioning

confidence: 99%

Humanized Mouse Models of Systemic Lupus Erythematosus: Opportunities and Challenges

et al. 2022

Self Cite

View full text Add to dashboard Cite

Animal models have played a crucial role in the understanding of the mechanisms and treatments of human diseases; however, owing to the large differences in genetic background and disease-specific characteristics, animal models cannot fully simulate the occurrence and progression of human diseases. Recently, humanized immune system mice, based on immunodeficient mice, have been developed that allow for the partial reconstruction of the human immune system and mimic the human in vivo microenvironment. Systemic lupus erythematosus (SLE) is a complex disease characterized by the loss of tolerance to autoantigens, overproduction of autoantibodies, and inflammation in multiple organ systems. The detailed immunological events that trigger the onset of clinical manifestations in patients with SLE are still not well known. Two methods have been adopted for the development of humanized SLE mice. They include transferring peripheral blood mononuclear cells from patients with SLE to immunodeficient mice or transferring human hematopoietic stem cells to immunodeficient mice followed by intraperitoneal injection with pristane to induce lupus. However, there are still several challenges to be overcome, such as how to improve the efficiency of reconstruction of the human B cell immune response, how to extend the lifespan and improve the survival rate of mice to extend the observation period, and how to improve the development of standardized commercialized models and use them. In summary, there are opportunities and challenges for the development of humanized mouse models of SLE, which will provide novel strategies for understanding the mechanisms and treatments of SLE.

show abstract

“…The MSCs also display a wide range of immunomodulatory properties (21). MSCs transplantation (MSCT) displayed therapeutic effects on various autoimmune diseases, including systemic lupus erythematosus (22,23), SS (24), and rheumatoid arthritis (25,26). Our previous study showed that allogeneic MSCs prevented and suppressed SS-like symptoms in non-obese diabetic (NOD) mice (27).…”

Section: Introductionmentioning

confidence: 99%

Umbilical cord mesenchymal stem cells alleviate Sjögren’s syndrome and related pulmonary inflammation through regulating Vγ4+ IL-17+ T cells

Ye¹,

Tang²,

Wang³

et al. 2022

Ann Transl Med

View full text Add to dashboard Cite

Background: Since gamma delta (γδ) T cells are involved in various autoimmune diseases, we aimed to verify whether γδ T cells participate in the pathogenesis of Sjögren's syndrome (SS) and related pulmonary inflammation, and also aimed to evaluate the effects of umbilical cord mesenchymal stem cells (MSCs) on SS-related pulmonary inflammation and the γδ T cells.Methods: The saliva flow rates of female non-obese diabetic (NOD/Ltj) mice were measured.Histopathologic analysis was performed in salivary glands (SG) and lung tissues. The levels of γδ T cells and their subsets in the peripheral blood, spleen, and lung were examined by flow cytometry. The purified γδ T cells were adoptively transferred into NOD/Ltj mice. MSC transplantation was performed in 8-week-old NOD/Ltj mice. Results:The results showed lymphocytic infiltration in SG and lacrimal glands (LG), and reduction of saliva flow rates in 8-week NOD/Ltj mice. The levels of γδ T cells decreased in peripheral blood, but increased in the lung of 8-and 12-week-old NOD/Ltj mice. The proportions and numbers of Vγ4 + T cells and Vγ4 + IL-17A + T cells increased in the lung, but decreased in peripheral blood of 8-week-old NOD/Ltj mice. Notably, transfer of γδ T cells decreased the rate of saliva flow, as well as aggravated the pathological changes in the lung. The transplantation of MSCs increased saliva flow rate and alleviated pathological injury in the SG and lung. The frequencies of Vγ4 + T cells and Vγ4 + IL-17A + T cells in the lung and spleen significantly decreased after MSC treatment. Our results demonstrated that γδ T cells and Vγ4+T cells contribute to the pathogenesis of SS and SS-related pulmonary inflammation. In addition, MSCs relieved SS and SS-related pulmonary inflammation through suppressing Vγ4 + IL-17A + T cells.Conclusions: Peripheral Vγ4 + T cells infiltrate into the lung in SS mice, and aggravate the symptoms of SS and SS-related pulmonary inflammation by secreting IL-17A. Meanwhile, lymphocyte infiltration could be reversed by MSC transplantation, which indicates the potential of MSCs in the treatment of SS and SSrelated pulmonary inflammation patients.

show abstract

Mesenchymal Stem Cell Therapy: Hope for Patients With Systemic Lupus Erythematosus

Cited by 47 publications

References 131 publications

Cell Based Treatment of Autoimmune Diseases in Children

Cell Based Treatment of Autoimmune Diseases in Children

Humanized Mouse Models of Systemic Lupus Erythematosus: Opportunities and Challenges

Umbilical cord mesenchymal stem cells alleviate Sjögren’s syndrome and related pulmonary inflammation through regulating Vγ4+ IL-17+ T cells

Contact Info

Product

Resources

About